LACIDIPINE - PREVENTION OF VASCULAR DAMAGE INDUCED BY HYPERTENSION

被引:9
作者
GAVIRAGHI, G
MICHELI, D
TERRON, A
CRISTOFORI, P
机构
[1] Glaxo Research Laboratories, Glaxo SpA, Verona
关键词
DAHL-S RATS; HYPERTENSION; VASCULAR PROTECTION; LACIDIPINE;
D O I
10.1097/00005344-199102001-00002
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Lacidipine is a long-lasting 1,4-dihydropyridine calcium antagonist that has been reported to protect salt-loaded Dahl-S rats from vascular damage and accelerated mortality when it is administered prophylactically at 0.1 and 0.3 mg/kg p.o. once a day (equivalent to the recommended dose in humans). The aim of this study was to investigate the vasoprotective properties of lacidipine in Dahl-S rats that had already developed sustained hypertension after 4 weeks of a salt-rich diet. Although none of the dosages of lacidipine (0.3, 1, and 3 mg/kg) reduced the elevated values of blood pressure, an almost complete protection from mortality was obtained. Moreover, lacidipine dose-dependently inhibited the development of macroscopic and microscopic alterations in the distal branches of mesenteric arteries and in the brain. A clear regression of vascular damage and cardiac hypertrophy was observed at the highest dose tested (3 mg/kg). These findings further support the assumption that the protective properties of lacidipine are not restricted to a reduction in blood pressure.
引用
收藏
页码:S7 / S12
页数:6
相关论文
共 13 条
[1]   REMODELING OF THE VASCULAR TREE IN HYPERTENSION - DRUG EFFECTS [J].
BOUDIER, HAJS ;
VANBORTEL, LMAB ;
DEMEY, JGR .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1990, 11 (06) :240-245
[2]   VASCULAR PROTECTION OF LACIDIPINE IN SALT-LOADED DAHL-S RATS AT NONSUSTAINED ANTIHYPERTENSIVE DOSES [J].
CRISTOFORI, P ;
TERRON, A ;
MICHELI, D ;
BERTOLINI, G ;
GAVIRAGHI, G ;
CARPI, C .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1991, 17 :S75-S86
[3]   THE EFFECTS OF LONG-TERM ADMINISTRATION OF PRAZOSIN ON THE MICROCIRCULATION IN SKELETAL-MUSCLES [J].
DAWSON, JM ;
HUDLICKA, O .
CARDIOVASCULAR RESEARCH, 1989, 23 (11) :913-920
[4]   THE ROLE OF CALCIUM IN THE PATHOGENESIS OF EXPERIMENTAL ARTERIOSCLEROSIS [J].
FLECKENSTEIN, A ;
FREY, M ;
ZORN, J ;
FLECKENSTEINGRUN, G .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1987, 8 (12) :496-501
[5]   SPECIFIC PHARMACOLOGY OF CALCIUM IN MYOCARDIUM, CARDIAC-PACEMAKERS, AND VASCULAR SMOOTH-MUSCLE [J].
FLECKENSTEIN, A .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1977, 17 :149-166
[6]  
FLECKENSTEIN A, 1990, HYPERTENSION PATHOPH, P471
[7]  
FREY M, 1988, ANN NY ACAD SCI, V522, P420
[8]   LONG-TERM MICROVASCULAR RESPONSE TO HYDRALAZINE IN SPONTANEOUSLY HYPERTENSIVE RATS [J].
HUTCHINS, PM ;
MARSHBURN, TH ;
MAULTSBY, SJ ;
LYNCH, CD ;
SMITH, TL ;
DUSSEAU, JW .
HYPERTENSION, 1988, 12 (01) :74-79
[9]  
KAZDA S, 1987, European Heart Journal, V8, P35
[10]   PHARMACOLOGY OF LACIDIPINE, A VASCULAR-SELECTIVE CALCIUM-ANTAGONIST [J].
MICHELI, D ;
RATTI, E ;
TOSON, G ;
GAVIRAGHI, G .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1991, 17 :S1-S8